Compounds > lutetium
Page last updated: 2024-08-22

lutetium and Neoplasm Metastasis

lutetium has been researched along with Neoplasm Metastasis in 63 studies

Research

Studies (63)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (4.76)29.6817
2010's41 (65.08)24.3611
2020's19 (30.16)2.80

Authors

AuthorsStudies
Akgun, E; An, F; Aras, O; Beytur, F; Bilgic, S; Gulsen, F; Oklu, R; Sager, S; Sayman, HB; Toplutas, KN; Yeyin, N1
Boegemann, M; Kessel, K; Rahbar, K; Schäfers, M; Schlack, K; Seifert, R; Weckesser, M1
Bodei, L; Gönen, M; Krebs, S; Lewis, JS; Lohrmann, C; Lyashchenko, SK; O'Donoghue, JA; Pandit-Taskar, N; Raj, N; Reidy-Lagunes, D; Staton, KD; Weber, WA1
Flechsig, P; Giesel, FL; Haberkorn, U; Hohenfellner, M; Holland-Letz, T; Kopka, K; Kratochwil, C; Mavriopoulou, E; Mier, W; Rathke, H; Röhrich, M1
Demirkol, MO; Falay, FO; Özkan, A; Seymen, H; Uçar, B; Yildiz Yarar, Y1
Cala, L; D'Alessandria, C; Eiber, M; Franz, C; Gafita, A; Heck, MM; Rauscher, I; Retz, M; Tauber, R; Weber, WA1
Bengel, FM; Derlin, T; Henkenberens, C; Ross, TL; Schmuck, S; Sommerlath Sohns, JM; von Klot, CAJ1
Akbarian, R; Fattahi, K; Ghodsirad, MA; Javanmard, B; Kaghazchi, F; Pirayesh, E; Tavakoli, M1
Barna, S; Blaickner, M; Grubmüller, B; Hartenbach, M; Haug, AR; Kramer, G; Rasul, S1
Aryana, K; Askari, E; Divband, G; Moghadam, SZ1
Cordes, M; Götz, TI; Kuwert, T; Lang, EW; Ludwig, B; Prante, O; Ritt, P; Schmidkonz, C1
Pirayesh, E1
Ahmadzadehfar, H; Alamdar, R; Attenberger, U; Conrad, R; Essler, M; Marinova, M; Mücke, M1
Mittal, BR; Satapathy, S; Sood, A1
Armstrong, AJ; George, DJ; Harrison, MR; Hoimes, CJ; Kao, C; Karachaliou, GS; Powers, E; Zhang, T1
Beheshti, A; Bruchertseifer, F; D'Alessandria, C; Eiber, M; Feuerecker, B; Gafita, A; Gschwend, JE; Heck, M; Knorr, K; Kratochwil, C; Morgenstern, A; Pickhard, A; Retz, M; Seidl, C; Tauber, R; Weber, WA1
Amthauer, H; Brenner, W; De Santis, M; Erber, B; Huang, K; Lindquist, RL; Radojewski, P; Rogasch, JMM; Schatka, I1
Leeuwenkamp, OR; Reed, N; Smith-Palmer, J; Virk, J1
Das, CK; Mittal, BR; Parihar, AS; Satapathy, S; Sood, A1
Civan, C; Ekenel, M; Has Simsek, D; Kuyumcu, S; Sanli, Y1
Aranda-Lara, L; Azorín-Vega, E; Nava-Cabrera, M; Oros-Pantoja, R1
Ahmadzadehfar, H; Becker, A; Eppard, E; Essler, M; Feldmann, G; Fisang, C; Kürpig, S; Yordanova, A1
Bögemann, M; Bräuer, A; Grubert, LS; Rahbar, K; Roll, W; Schäfers, M; Schrader, AJ1
Boegemann, M; Rahbar, K; Schrader, AJ1
Baum, RP; Klette, I; Kulkarni, HR; Osterkamp, F; Reineke, U; Schuchardt, C; Singh, A; Smerling, C; Wiessalla, S1
Ahmadzadehfar, H; Boegemann, M; Essler, M; Eveslage, M; Rahbar, K; Schäfers, M; Yordanova, A1
Ahmadzadehfar, H; Bögeman, M; Essler, M; Eveslage, M; Rahbar, K; Schäfers, M; Yordanova, A1
Ahmadzadehfar, H; Boegemann, M; Rahbar, K1
Joensuu, T; Kairemo, K; Kiljunen, T; Roviello, G; Uprimny, C; Virgolini, I; von Eyben, FE1
Ahmadzadehfar, H; Essler, M1
Ahmadzadehfar, H; Bundschuh, RA; Eppard, E; Essler, M; Gaertner, FC; Khawar, A; Kürpig, S; Meisenheimer, M; Roesch, F; Sinnes, JP1
Akhurst, T; Eu, P; Ferdinandus, J; Hicks, RJ; Hofman, MS; Iravani, A; Jackson, P; Kong, G; Murphy, DG; Ravi Kumar, A; Sandhu, S; Scalzo, M; Thang, SP; Violet, J; Williams, SG1
Cho, EH; Chung, C; Dho, SH; Jung, SH; Kim, JY; Kim, LK; Kim, SY; Lee, J; Lee, SY; Lim, JC; Min, SW1
Bednarz, B; Lee, D; Li, M; Schultz, MK1
Bögemann, M; Bräuer, A; Rahbar, K; Roll, W; Weckesser, M1
Kim, YI; Kim, YJ1
Gans, R; Lam, M; Stam, A; van Kalmthout, L1
Banerjee, S; Basu, S; Joshi, A; Parghane, RV; Prabhash, K1
Cooperberg, M; Eapen, RS; Hofman, MS; Lawrentschuk, N; Murphy, DG; Nzenza, TC1
Ahmadzadehfar, H; Essler, M; Feldmann, G; Gaertner, FC; Hauser, S; Kürpig, S; Linden, P; Meisenheimer, M; Yordanova, A1
Baltzer, P; D'Andrea, D; Eidherr, H; Grubmüller, B; Grubmüller, KH; Hacker, M; Hartenbach, M; Haug, AR; Kramer, G; Mitterhauser, M; Pfaff, S; Senn, D; Shariat, SF; Wadsak, W1
Barber, TW; Baum, RP; Billah, B; Kulkarni, HR; Niepsch, K; Singh, A1
Bal, C; Ballal, S; Dwivedi, SN; Sahoo, RK; Yadav, MP1
Jüptner, M; Lützen, U; Marx, M; Zuhayra, M1
Agaoglu, FY; Has Simsek, D; Kuyumcu, S; Unal, SN1
D'Alessandria, C; Eiber, M; Gafita, A; Tauber, R; Wang, H; Weber, WA1
Al-Ejeh, F; Brown, MP; Chenevix-Trench, G; Khanna, KK; Lakhani, SR; Miranda, M; Shi, W; Simpson, PT; Song, S; Swarbrick, A; Vargas, AC; Welm, AL; Wiegmans, AP1
Brandt-Larsen, M; Juhl, K; Kjaer, A; Madsen, J; Persson, M; Ploug, M; Rasmussen, P1
Guerra Liberal, FD; Tavares, AA; Tavares, JM1
Anderson, CJ; Beaino, W; Nedrow, JR1
Baum, RP; Beykan, S; Eiber, M; Klette, I; Kulkarni, HR; Lassmann, M; Schottelius, M; Schwaiger, M; Simecek, J; Weineisen, M; Wester, HJ; Yildiz, A1
Akyurek, S; Kucuk, NO; Ozkan, E; Soydal, C1
Baum, RP; Klette, I; Kulkarni, HR; Mueller, D; Schottelius, M; Schuchardt, C; Singh, A; Wester, HJ; Wiessalla, S; Wirtz, M1
Ahmadzadehfar, H; Essler, M; Knüpfer, E; Schlenkhoff, CD1
D'Alessandria, C; Eiber, M; Gschwend, JE; Heck, MM; Janssen, F; Maurer, T; Rauscher, I; Retz, M; Scheidhauer, K; Schottelius, M; Schwaiger, M; Storz, E; Tauber, R; Wester, HJ1
Bartenstein, P; Böning, G; Delker, A; Fendler, WP; Gildehaus, FJ; Gratzke, C; Ilhan, H; Lehner, S; Reinhardt, S; Rominger, A; Stief, C1
Bal, A; Bhusari, P; Dhawan, DK; Mittal, BR; Parmar, M; Shukla, J; Singh, G; Vatsa, R1
Garkavij, M; Ljungberg, M; Nickel, M; Ohlsson, T; Sjögreen-Gleisner, K; Strand, SE; Tennvall, J; Wingårdh, K1
Applebaum, L; Barak, D; Eckstein, J; Fraenkel, M; Gross, DJ; Grozinsky-Glasberg, S; Müeller-Brand, J; Shimon, I; Walter, MA1
Bander, NH; Goldsmith, SJ; Kostakoglu, L; Milowsky, MI; Nanus, DM; Vallabhajosula, S1
Bakker, WH; de Herder, WW; Feelders, RA; Kooij, PP; Krenning, EP; Kwekkeboom, DJ; van Essen, M; Wolbers, JG1
Baum, RP; Müller, D; Senftleben, S; Wehrmann, C; Zachert, C1

Reviews

7 review(s) available for lutetium and Neoplasm Metastasis

ArticleYear
Visceral Metastases as Predictors of Response and Survival Outcomes in Patients of Castration-Resistant Prostate Cancer Treated With 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy: A Systematic Review and Meta-analysis.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:12

    Topics: Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Treatment Outcome; Viscera

2020
Novel therapies are changing treatment paradigms in metastatic prostate cancer.
    Journal of hematology & oncology, 2020, 10-28, Volume: 13, Issue:1

    Topics: Androgen Receptor Antagonists; Animals; Antineoplastic Agents; Clinical Trials as Topic; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes

2020
[
    Der Urologe. Ausg. A, 2017, Volume: 56, Issue:11

    Topics: Compassionate Use Trials; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies

2017
Third-line treatment and
    European journal of nuclear medicine and molecular imaging, 2018, Volume: 45, Issue:3

    Topics: Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes

2018
Therapeutic Responses and Survival Effects of 177Lu-PSMA-617 Radioligand Therapy in Metastatic Castrate-Resistant Prostate Cancer: A Meta-analysis.
    Clinical nuclear medicine, 2018, Volume: 43, Issue:10

    Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Survival Analysis; Treatment Outcome

2018
PSMA PET applications in the prostate cancer journey: from diagnosis to theranostics.
    World journal of urology, 2019, Volume: 37, Issue:7

    Topics: Dipeptides; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Membrane Glycoproteins; Neoplasm Metastasis; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Theranostic Nanomedicine

2019
Radioligand Therapy With
    AJR. American journal of roentgenology, 2019, Volume: 213, Issue:2

    Topics: Humans; Lutetium; Male; Neoplasm Metastasis; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes

2019

Trials

6 trial(s) available for lutetium and Neoplasm Metastasis

ArticleYear
Selective Intra-Arterial Lutetium-177-Labeled Prostate-Specific Membrane Antigen Therapy for Castration-Resistant Prostate Cancer: Initial Results.
    Journal of vascular and interventional radiology : JVIR, 2022, Volume: 33, Issue:3

    Topics: Humans; Lutetium; Male; Neoplasm Metastasis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Treatment Outcome

2022
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2019, 12-01, Volume: 25, Issue:23

    Topics: Adult; Aged; Chelating Agents; Female; Follow-Up Studies; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Prognosis; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin; Young Adult

2019
Improving quality of life in patients with metastatic prostate cancer following one cycle of 177Lu-PSMA-617 radioligand therapy: a pilot study.
    Nuklearmedizin. Nuclear medicine, 2020, Volume: 59, Issue:6

    Topics: Aged; Aged, 80 and over; Bone Neoplasms; Humans; Liver Neoplasms; Lung Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome

2020
[
    The Lancet. Oncology, 2018, Volume: 19, Issue:6

    Topics: Aged; Dipeptides; Disease Progression; Health Status; Heterocyclic Compounds, 1-Ring; Humans; Kallikreins; Lutetium; Male; Neoplasm Metastasis; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Quality of Life; Radioisotopes; Radiopharmaceuticals; Time Factors; Treatment Outcome; Victoria

2018
Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
    International journal of cancer, 2017, 02-15, Volume: 140, Issue:4

    Topics: Adult; Antineoplastic Agents, Hormonal; Breast Neoplasms; Combined Modality Therapy; Feasibility Studies; Female; Genes, erbB-2; Heterocyclic Compounds, 1-Ring; Humans; Immunoconjugates; Lutetium; Mastectomy; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Proteins; Pilot Projects; Radioimmunotherapy; Radioisotopes; Receptor, ErbB-2; Single Photon Emission Computed Tomography Computed Tomography; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tamoxifen; Tissue Distribution; Trastuzumab

2017
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jul-20, Volume: 23, Issue:21

    Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal; Bone Marrow; Cell Membrane; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging

2005

Other Studies

50 other study(ies) available for lutetium and Neoplasm Metastasis

ArticleYear
Second line chemotherapy and visceral metastases are associated with poor survival in patients with mCRPC receiving
    Theranostics, 2019, Volume: 9, Issue:17

    Topics: Aged; Aged, 80 and over; Androstenes; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Taxoids

2019
Response Prediction of
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020, Volume: 61, Issue:5

    Topics: Aged; Biomarkers, Tumor; Chromogranin A; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; L-Lactate Dehydrogenase; Ligands; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome

2020
Posttherapeutic Critical Organ Dosimetry of Extensive 177Lu-PSMA Inhibitor Therapy With Metastatic Castration-Resistant Prostate Cancer: One Center Results.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:4

    Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Organs at Risk; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radiopharmaceuticals; Radiotherapy Dosage

2020
Early Prostate-Specific Antigen Changes and Clinical Outcome After
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2020, Volume: 61, Issue:10

    Topics: Aged; Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Retrospective Studies

2020
Influence of short-term dexamethasone on the efficacy of
    The Prostate, 2020, Volume: 80, Issue:8

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemoradiotherapy; Cohort Studies; Dexamethasone; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Retrospective Studies

2020
Diagnostic Utility of Lutetium-177 (Lu 177) Prostate-Specific Membrane Antigen (PSMA) Scintigraphy In Prostate Cancer Patients With PSA Rise And Negative Conventional Imaging.
    Urology journal, 2020, 06-23, Volume: 17, Issue:4

    Topics: Aged; Aged, 80 and over; Dipeptides; Evans Blue; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Radiopharmaceuticals; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon

2020
Dose Calculations and Dose-Effect Relationships in 177Lu-PSMA I&T Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:9

    Topics: Aged; Aged, 80 and over; Dipeptides; Dose-Response Relationship, Radiation; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Membrane Glycoproteins; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radiometry; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted

2020
Whole-Body 177Lu-Prostate-Specific Membrane Antigen Scan Pattern With Excess Free 177Lu-Chloride in a Metastatic Castration-Resistant Prostate Cancer Patient.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:10

    Topics: Artifacts; Chlorides; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome; Whole Body Imaging

2020
Estimation of [177Lu]PSMA-617 tumor uptake based on voxel-wise 3D Monte Carlo tumor dosimetry in patients with metastasized castration resistant prostate cancer.
    Nuklearmedizin. Nuclear medicine, 2020, Volume: 59, Issue:5

    Topics: Biological Transport; Humans; Lutetium; Male; Middle Aged; Monte Carlo Method; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiometry

2020
Radioligand Therapy With 177Lu-Prostate-Specific Membrane Antigen in a Patient With Non-Prostate-Specific Antigen-Secreting Metastatic Prostate Cancer.
    Clinical nuclear medicine, 2020, Volume: 45, Issue:10

    Topics: Aged; Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Treatment Outcome

2020
Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
    European urology, 2021, Volume: 79, Issue:3

    Topics: Actinium; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome; Xerostomia

2021
Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with
    Annals of nuclear medicine, 2021, Volume: 35, Issue:3

    Topics: Aged; Aged, 80 and over; Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Retrospective Studies; Treatment Outcome

2021
Lutetium oxodotreotide (
    BMC cancer, 2021, Jan-05, Volume: 21, Issue:1

    Topics: Cost-Benefit Analysis; Disease Progression; Follow-Up Studies; Humans; Intestinal Neoplasms; Lutetium; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Prognosis; Quality-Adjusted Life Years; Radiopharmaceuticals; Stomach Neoplasms

2021
Response to Concomitant Enzalutamide and 177Lu-PSMA-617 Radioligand Therapy in ATM-Mutated Metastatic Castration Resistant Prostate Cancer.
    Clinical nuclear medicine, 2021, Jul-01, Volume: 46, Issue:7

    Topics: Aged; Benzamides; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Nitriles; Phenylthiohydantoin; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome

2021
177Lu-PSMA Therapy for Metastatic Testicular Mixed Germ Cell Tumor.
    Clinical nuclear medicine, 2021, May-01, Volume: 46, Issue:5

    Topics: Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Neoplasms, Germ Cell and Embryonal; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms; Testicular Neoplasms

2021
Comparison between
    Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine, 2021, Volume: 176

    Topics: Actinium; Animals; Bone Neoplasms; Cell Line, Tumor; Disease Models, Animal; Humans; Lutetium; Mice, Nude; Neoplasm Metastasis; Radioisotopes; Radiometry

2021
The impact of repeated cycles of radioligand therapy using [
    European journal of nuclear medicine and molecular imaging, 2017, Volume: 44, Issue:9

    Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Hormones; Humans; Kidney; Ligands; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Risk Factors; Time Factors; Treatment Failure

2017
    European journal of nuclear medicine and molecular imaging, 2017, Volume: 44, Issue:10

    Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Safety; Survival Analysis; Treatment Outcome

2017
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018, Volume: 59, Issue:5

    Topics: Adenocarcinoma; Aged; Carcinoma, Pancreatic Ductal; Combined Modality Therapy; Drug Design; Female; Humans; Injections, Intravenous; Kidney; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Pancreatic Neoplasms; Quality of Life; Radiometry; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Neurotensin; Retrospective Studies; Salvage Therapy; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed; Treatment Outcome

2018
PSMA targeted radioligandtherapy in metastatic castration resistant prostate cancer after chemotherapy, abiraterone and/or enzalutamide. A retrospective analysis of overall survival.
    European journal of nuclear medicine and molecular imaging, 2018, Volume: 45, Issue:1

    Topics: Aged; Antigens, Surface; Dipeptides; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals; Survival Analysis

2018
Delayed response after repeated
    European journal of nuclear medicine and molecular imaging, 2018, Volume: 45, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Time Factors; Treatment Outcome

2018
    European journal of nuclear medicine and molecular imaging, 2018, Volume: 45, Issue:3

    Topics: Clinical Trials, Phase III as Topic; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant

2018
Predictive Factors of Response and Overall Survival in Patients with Castration-Resistant Metastatic Prostate Cancer Undergoing
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018, Volume: 59, Issue:7

    Topics: Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Survival Analysis

2018
Prediction of Normal Organ Absorbed Doses for [177Lu]Lu-PSMA-617 Using [44Sc]Sc-PSMA-617 Pharmacokinetics in Patients With Metastatic Castration Resistant Prostate Carcinoma.
    Clinical nuclear medicine, 2018, Volume: 43, Issue:7

    Topics: Aged; Carcinoma; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiation Dosage; Radiopharmaceuticals; Radiotherapy Dosage; Radiotherapy Planning, Computer-Assisted; Scandium

2018
Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer.
    Scientific reports, 2018, 06-12, Volume: 8, Issue:1

    Topics: Animals; Antineoplastic Agents, Immunological; Carcinoma, Non-Small-Cell Lung; CD55 Antigens; Cell Line, Tumor; Humans; Isotope Labeling; Lung Neoplasms; Lutetium; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Metastasis; Neoplasm Proteins; Pleural Neoplasms; Radioimmunotherapy; Radioisotopes; Theranostic Nanomedicine; Xenograft Model Antitumor Assays

2018
Modeling Cell and Tumor-Metastasis Dosimetry with the Particle and Heavy Ion Transport Code System (PHITS) Software for Targeted Alpha-Particle Radionuclide Therapy.
    Radiation research, 2018, Volume: 190, Issue:3

    Topics: Actinium; Alpha Particles; Beta Particles; Bismuth; Dose-Response Relationship, Radiation; Humans; Lead Radioisotopes; Lutetium; Neoplasm Metastasis; Neoplasms; Radioisotopes; Yttrium Radioisotopes

2018
Long-term Survival and Excellent Response to Repeated 177Lu-Prostate-Specific Membrane Antigen 617 Radioligand Therapy in a Patient With Advanced Metastatic Castration-Resistant Prostate Cancer.
    Clinical nuclear medicine, 2018, Volume: 43, Issue:10

    Topics: Aged; Dipeptides; Disease-Free Survival; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Treatment Outcome

2018
Visual deficit possibly caused by lutetium-177 PSMA treatment.
    BMJ case reports, 2018, Oct-08, Volume: 2018

    Topics: Bone Neoplasms; Diagnosis, Differential; Humans; Lutetium; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radiation Injuries; Radioisotopes; Radiopharmaceuticals; Vision Disorders

2018
The rationality of combining second-generation antiandrogens with 177Lu-PSMA or its alpha-emitting congeners for better and durable results: will this dominate the therapeutic landscape and be an upfront consideration in metastatic castration-resistant pr
    Nuclear medicine communications, 2018, Volume: 39, Issue:12

    Topics: Alpha Particles; Androgen Antagonists; Antigens, Surface; Combined Modality Therapy; Glutamate Carboxypeptidase II; Humans; Lutetium; Male; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Treatment Outcome

2018
Outcome and safety of rechallenge [
    European journal of nuclear medicine and molecular imaging, 2019, Volume: 46, Issue:5

    Topics: Aged; Aged, 80 and over; Dipeptides; Feasibility Studies; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Safety; Survival Analysis; Treatment Outcome

2019
Response assessment using
    European journal of nuclear medicine and molecular imaging, 2019, Volume: 46, Issue:5

    Topics: Aged; Dipeptides; Follow-Up Studies; Gallium Isotopes; Gallium Radioisotopes; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Membrane Glycoproteins; Neoplasm Metastasis; Organometallic Compounds; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; ROC Curve; Survival Analysis; Treatment Outcome

2019
Clinical Outcomes of
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2019, Volume: 60, Issue:7

    Topics: Aged; Aged, 80 and over; Bridged-Ring Compounds; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Ligands; Lutetium; Male; Neoplasm Metastasis; Progression-Free Survival; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Retrospective Studies; Safety; Taxoids; Time Factors; Treatment Outcome

2019
Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma.
    Nuklearmedizin. Nuclear medicine, 2019, Volume: 58, Issue:4

    Topics: Dipeptides; Female; Heterocyclic Compounds, 1-Ring; Humans; Leiomyosarcoma; Ligands; Lutetium; Middle Aged; Neoplasm Metastasis; Prostate-Specific Antigen

2019
Radionuclide Therapy With 177Lu-PSMA in a Case of Metastatic Adenoid Cystic Carcinoma of the Parotid.
    Clinical nuclear medicine, 2019, Volume: 44, Issue:9

    Topics: Carcinoma, Adenoid Cystic; Female; Glutamate Carboxypeptidase II; Humans; Lutetium; Middle Aged; Neoplasm Metastasis; Parotid Neoplasms; Radioisotopes

2019
Exceptional 4-year response to
    European journal of nuclear medicine and molecular imaging, 2019, Volume: 46, Issue:10

    Topics: Aged; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiopharmaceuticals

2019
Treatment of triple-negative breast cancer using anti-EGFR-directed radioimmunotherapy combined with radiosensitizing chemotherapy and PARP inhibitor.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Volume: 54, Issue:6

    Topics: Animals; Antibodies, Monoclonal; Breast Neoplasms; Cell Line, Tumor; Cell Transformation, Neoplastic; Enzyme Inhibitors; ErbB Receptors; Female; Lutetium; Mice; Neoplasm Metastasis; Poly(ADP-ribose) Polymerase Inhibitors; Radiation-Sensitizing Agents; Radioimmunotherapy; Radioisotopes; RNA, Messenger

2013
uPAR targeted radionuclide therapy with (177)Lu-DOTA-AE105 inhibits dissemination of metastatic prostate cancer.
    Molecular pharmaceutics, 2014, Aug-04, Volume: 11, Issue:8

    Topics: Animals; Cell Line, Tumor; Coordination Complexes; Disease-Free Survival; Enzyme-Linked Immunosorbent Assay; Flow Cytometry; Humans; Inhibitory Concentration 50; Ligands; Lutetium; Male; Mice; Neoplasm Invasiveness; Neoplasm Metastasis; Oligopeptides; Positron-Emission Tomography; Prostatic Neoplasms; Protein Binding; Radioisotopes; Receptors, Urokinase Plasminogen Activator; Recombinant Proteins; Treatment Outcome; X-Ray Microtomography

2014
Comparative analysis of 11 different radioisotopes for palliative treatment of bone metastases by computational methods.
    Medical physics, 2014, Volume: 41, Issue:11

    Topics: Algorithms; Beta Particles; Bone Neoplasms; Computer Simulation; DNA; DNA Damage; DNA Repair; Humans; Lutetium; Monte Carlo Method; Neoplasm Metastasis; Palliative Care; Radioisotopes; Radiopharmaceuticals; Radium; Rhenium; Samarium; Strontium Radioisotopes

2014
Evaluation of (68)Ga- and (177)Lu-DOTA-PEG4-LLP2A for VLA-4-Targeted PET Imaging and Treatment of Metastatic Melanoma.
    Molecular pharmaceutics, 2015, Jun-01, Volume: 12, Issue:6

    Topics: Animals; Cell Line, Tumor; Gallium Radioisotopes; Humans; Integrin alpha4beta1; Lutetium; Male; Melanoma; Melanoma, Cutaneous Malignant; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Neoplasm Metastasis; Positron-Emission Tomography; Radioisotopes; Skin Neoplasms

2015
68Ga- and 177Lu-Labeled PSMA I&T: Optimization of a PSMA-Targeted Theranostic Concept and First Proof-of-Concept Human Studies.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015, Volume: 56, Issue:8

    Topics: Aged; Anhydrides; Animals; Antigens, Surface; Cell Line, Tumor; Contrast Media; Coordination Complexes; Female; Gallium Radioisotopes; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Inhibitory Concentration 50; Kinetics; Lutetium; Male; Mice; Middle Aged; Neoplasm Metastasis; Neoplasm Transplantation; Oligopeptides; Positron-Emission Tomography; Prostatic Neoplasms; Radiometry; Radiotherapy

2015
SNMMI 2015 Image of the Year.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2015, Volume: 56, Issue:8

    Topics: Antigens, Surface; Awards and Prizes; Baltimore; Dipeptides; Gallium; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; History, 21st Century; Humans; Lutetium; Male; Neoplasm Metastasis; Nuclear Medicine; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radionuclide Imaging; Societies, Medical

2015
Marked Response to 177Lu Prostate-Specific Membrane Antigen Treatment in Patient With Metastatic Prostate Cancer.
    Clinical nuclear medicine, 2016, Volume: 41, Issue:2

    Topics: Edetic Acid; Gallium Isotopes; Gallium Radioisotopes; Humans; Lutetium; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Oligopeptides; Positron-Emission Tomography; Prostatic Neoplasms; Radiopharmaceuticals; Tomography, X-Ray Computed

2016
177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2016, Volume: 57, Issue:7

    Topics: Aged; Antigens, Surface; Cohort Studies; Dipeptides; Disease-Free Survival; Edetic Acid; Erythrocyte Count; Gallium Isotopes; Gallium Radioisotopes; Glutamate Carboxypeptidase II; Heterocyclic Compounds, 1-Ring; Humans; Leukocyte Count; Lutetium; Male; Neoplasm Metastasis; Oligopeptides; Organometallic Compounds; Pain; Patient Selection; Positron-Emission Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiometry; Radiopharmaceuticals; Treatment Outcome

2016
Metastatic Prostate Cancer With Restored Hormone-Response After Radioligand Therapy With 177Lu-PSMA-617.
    Clinical nuclear medicine, 2016, Volume: 41, Issue:7

    Topics: Aged, 80 and over; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Treatment Outcome

2016
Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.
    The Journal of urology, 2016, Volume: 196, Issue:2

    Topics: Adenocarcinoma; Aged; Antigens, Surface; Glutamate Carboxypeptidase II; Humans; Ligands; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms, Castration-Resistant; Radioisotopes; Radiopharmaceuticals; Retrospective Studies; Treatment Outcome

2016
Preliminary experience with dosimetry, response and patient reported outcome after 177Lu-PSMA-617 therapy for metastatic castration-resistant prostate cancer.
    Oncotarget, 2017, Jan-10, Volume: 8, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Cohort Studies; Combined Modality Therapy; Dipeptides; Heterocyclic Compounds, 1-Ring; Humans; Lutetium; Male; Middle Aged; Neoplasm Grading; Neoplasm Metastasis; Neoplasm Staging; Patient Reported Outcome Measures; Prostate-Specific Antigen; Prostatic Neoplasms, Castration-Resistant; Radiometry; Retreatment

2017
177Lu-[DOTA0,Tyr3] octreotate therapy in patients with disseminated neuroendocrine tumors: Analysis of dosimetry with impact on future therapeutic strategy.
    Cancer, 2010, Feb-15, Volume: 116, Issue:4 Suppl

    Topics: Forecasting; Humans; Lutetium; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Radiometry; Radiopharmaceuticals; Radiotherapy Dosage

2010
Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas.
    Cancer, 2011, Apr-01, Volume: 117, Issue:7

    Topics: Adult; Aged; Aged, 80 and over; Disease Progression; Female; Gastrinoma; Humans; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Octreotide; Radioisotopes; Receptors, Peptide; Retrospective Studies; Tomography, X-Ray Computed; Treatment Outcome; Yttrium Radioisotopes

2011
Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2006, Volume: 47, Issue:10

    Topics: Adult; Aged; Carcinoma, Small Cell; Eye Neoplasms; Female; Humans; Lung Neoplasms; Lutetium; Male; Melanoma; Meningeal Neoplasms; Meningioma; Middle Aged; Neoplasm Metastasis; Octreotide; Paraganglioma; Radioisotopes; Radiopharmaceuticals

2006
Results of individual patient dosimetry in peptide receptor radionuclide therapy with 177Lu DOTA-TATE and 177Lu DOTA-NOC.
    Cancer biotherapy & radiopharmaceuticals, 2007, Volume: 22, Issue:3

    Topics: Adult; Aged; Bone Neoplasms; Female; Heterocyclic Compounds, 1-Ring; Humans; Liver Neoplasms; Lutetium; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Radioisotopes; Radiotherapy; Radiotherapy Dosage; Receptors, Peptide; Tomography, X-Ray Computed

2007